Business

Biotech, pharma, and money in science

Daniel O'Day
Biotech

CEO Daniel O’Day explains why Gilead paid $4.9 billion for Forty Seven

By Matthew Herper

Sangamo zinc fingers illo
Biotech

Biogen, Sangamo partner to develop genome-editing therapies for Alzheimer’s and Parkinson’s disease

By Adam Feuerstein

Graph Vs Host Disease
Biotech

With strong data on lead drug, Kadmon and CEO Harlan Waksal plot their redemption

By Adam Feuerstein

Frank Reynolds, CEO of PixarBio, sentenced to 7 years for defrauding investors
Biotech

Biotech founder who said his painkiller would replace opioids sentenced to 7 years in prison

By Jonathan Saltzman — Boston Globe

Scale close up
Biotech

Weight-loss drug to be pulled from market after FDA expresses concerns on cancer risk

By Adam Feuerstein

Radiologists supervise MRI
Opinions Plus

Why medtech is a different beast than biotech in the life sciences pack

By Jonathan P. Gertler

ProstateCancerCell
Biotech

With new combination drug data, Exelixis takes another shot at prostate cancer treatment

By Adam Feuerstein

Daniel O'Day STAT Summit
Adam's Take

Investor impatience with Gilead reclamation project sparks acquisition chatter

By Adam Feuerstein

DNA Editing
Biotech

Beam Therapeutics raises $180 million in IPO

By Jonathan Saltzman — Boston Globe

Best Buy
Health Tech

Big Tech aimed to disrupt health care. Big Retail may be better positioned to do so

By Erin Brodwin

Biotech

Biogen wins patent challenge to key multiple sclerosis drug

By Adam Feuerstein

Kenneth Frazier
Business

Merck to spin off new $6.5 billion firm focused on women’s health, older drugs

By Matthew Herper

Jorge Conde Andreessen Horowitz
Exclusive

This VC firm once pledged to never invest in health care. Now it’s launching its third life sciences fund

By Erin Brodwin

Peanut allergy treatment
Biotech

FDA approves the first treatment for peanut allergy, but commercial success is hardly assured

By Adam Feuerstein

Biotech

European regulators could take a harder line on the review of an Agios blood cancer drug

By Adam Feuerstein

Adam's Take

As Biogen gets squishy on timing for an aducanumab filing, the clock is ticking

By Adam Feuerstein

Hepatitis C virus model
Biotech

Spring Bank scraps hepatitis R&D after patient dies in trial

By Jonathan Saltzman — Boston Globe

Business

Novartis gene therapy for fatal childhood disease delivers strong sales during fourth quarter

By Adam Feuerstein

Missing women
Biotech

Three star scientists announce plan to solve biotech’s ‘missing women’ problem

By Sharon Begley

Christina Nolan- VT AG
Business

Prosecutors identified ‘Pharma Co. X’ as central to alleged opioid kickback scheme. Was it Purdue?

By Andrew Joseph

2018 biotech outlook: Sunrise
Biotech

Biotech earnings preview: Unsettled investors hoping for strong 2020 outlooks

By Adam Feuerstein

Biotech

Acceleron pulmonary hypertension drug succeeds in mid-stage clinical trial

By Adam Feuerstein

Biotech

The suburbs are cheaper, but they don’t have what Kendall Square has for biotechs: serendipity

By Scott Kirsner — Boston Globe

Pharma

Insys founder gets 5½ years in jail for his role in fentanyl prescription scheme

By Jonathan Saltzman — Boston Globe

23andMe kits
Business

23andMe laying off 14% of employees amid slump in DNA spit kit sales

By Erin Brodwin

Subsys 1600 mcg video
Business

Former Insys executive who dressed as giant fentanyl bottle gets 26-month sentence

By Jonathan Saltzman — Boston Globe

Sunrise Lee, former Insys executive
Biotech

Two more former Insys executives get prison sentences

By Jonathan Saltzman — Boston Globe

Biotech

How swallowing a star might keep you from missing a dose of medicine

By Jonathan Saltzman — Boston Globe

Alexis Borisy and Melanie Nallicheri
Biotech

‘We have a tragedy of the commons’: How a VC thinks his new company can lower drug prices

By Adam Feuerstein and Matthew Herper

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy